halozyme.com (HALO) - Company Sales Revenue

Halozyme Therapeutics, Inc. - graphic logo of issuer HALO

The product realization trend for Halozyme Therapeutics (HALO) correlates with the growth of ENHANZE licensing payments and share buybacks, while 1.80 indicates the level of this metric. The business is based on innovations to convert therapies into a subcutaneous format for patient comfort. However, financial stability requires monitoring due to the potential expiration of patent protection by 2030.

Halozyme Corp (HALO): Company Revenue from 07/04/2022 to 11/18/2026

Analytical breakdowns for Halozyme (HALO)

General company analysis:HALO (halozyme.com)
Original product of halozyme.com

Sales represent the aggregate cash flow from product realization over the reporting period. By analyzing the sales revenue of Halozyme Therapeutics (HALO), an investor assesses the business's actual market resilience to macroeconomic shocks. This metric measures actual demand, which is sensitive to the pace of post-crisis recovery. The stability of this indicator is ensured by the monopoly right of Halozyme Therapeutics (HALO) to royalties. Inelastic demand for ENHANZE technology guarantees predictable revenue growth.

Analysis of competing companies

Company Revenue ONC|Company Revenue Revolution Medicines, Inc. (RVMD)|Revenue and Sales Volume Ascentage Pharma Group International (AAPG)|Revenue and Sales Volume CGON (CG Oncology Inc)|Company Sales Revenue URGN|bicara.com - Revenue and Sales Volume|Company Sales Revenue PSNL (personalis.com)|Erasca Inc (ERAS) - Company Revenue|Company Sales Delcath Systems|YMAB (YmAbs) - Revenue and Sales Volume|AURA: Company Sales Revenue|Company Revenue Candel Therapeutics, Inc. (CADL)|Revenue and Sales Volume Accuray (ARAY)|Company Revenue SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Company Total Revenue|CTOR - Company Revenue|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue